Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Clinical Applications of PET in Brain Tumors
438
Zitationen
1
Autoren
2007
Jahr
Abstract
Malignant gliomas and metastatic tumors are the most common brain tumors. Neuroimaging plays a significant role clinically. In low-grade tumors, neuroimaging is needed to evaluate recurrent disease and to monitor anaplastic transformation into high-grade tumors. In high-grade and metastatic tumors, the imaging challenge is to distinguish between recurrent tumor and treatment-induced changes such as radiation necrosis. The current clinical gold standard, MRI, provides superior structural detail but poor specificity in identifying viable tumors in brain treated with surgery, radiation, or chemotherapy. (18)F-FDG PET identifies anaplastic transformation and has prognostic value. The sensitivity and specificity of (18)F-FDG in evaluating recurrent tumor and treatment-induced changes can be improved significantly by co-registration with MRI and potentially by delayed imaging 3-8 h after injection. Amino acid PET tracers are more sensitive than (18)F-FDG in imaging recurrent tumors and in particular recurrent low-grade tumors. They are also promising in differentiating between recurrent tumors and treatment-induced changes.
Ähnliche Arbeiten
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
2005 · 21.376 Zit.
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
2016 · 15.798 Zit.
The 2007 WHO Classification of Tumours of the Central Nervous System
2007 · 13.907 Zit.
CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2006-2010
2013 · 12.093 Zit.
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary
2021 · 11.333 Zit.